fluorouracil has been researched along with rosiglitazone in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abrahám, C; Benko, I; Djazayeri, K; Szilvássy, Z; Zsuga, J | 1 |
| Benko, I; Djazayeri, K; Kiss, A; Nagy, L; Németh, J; Peitl, B; Szabó, B; Szilvássy, Z | 1 |
| Benko, I; Benko, K; Djazayeri, K; Rózsa, B; Szabó, B; Szentmiklósi, AJ; Szilvássy, Z | 1 |
| Cao, JG; Dong, L; Liu, HQ; Qin, Y; Sun, L; Tang, XQ; Xia, H; Zhang, YQ | 1 |
| Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q | 1 |
| Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB | 1 |
| Chai, Z; Li, L; Liu, C; Shen, X; Wang, L; Zhang, X; Zhang, Z | 1 |
| Hu, J; Jing, X; Li, W; Su, P; Wang, X; Wu, X; Zhang, H; Zhang, X; Zhou, G | 1 |
| Feng, Y; Liu, K; Lu, W; Wang, S; Wang, W | 1 |
| Biti, G; Bonomo, P; Castiglione, F; Desideri, I; Francolini, G; Gerini, C; Grassi, R; Greto, D; Livi, L; Loi, M; Mangoni, M; Meattini, I; Perna, M; Salvatore, G; Sottili, M | 1 |
1 review(s) available for fluorouracil and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
18 other study(ies) available for fluorouracil and rosiglitazone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Female; Fluorouracil; Granulocytes; Hematopoietic Stem Cells; Hypoglycemic Agents; Injections, Intraperitoneal; Insulin Resistance; Macrophages; Mice; Neutropenia; Protective Agents; Rosiglitazone; Thiazolidinediones | 2003 |
Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment.
Topics: Administration, Oral; Anilides; Animals; Antimetabolites, Antineoplastic; Blood Glucose; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Precursor Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Hypoglycemic Agents; Injections, Intraperitoneal; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Bone Regeneration; Female; Fluorouracil; Granulocytes; Hypoglycemic Agents; Leukocyte Count; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutrophils; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.
Topics: Anilides; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Gene Expression Regulation; Humans; Hypoglycemic Agents; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cyclooxygenase 2; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; PPAR alpha; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Tumor Cells, Cultured | 2009 |
Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Fluorouracil; Gene Silencing; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; PPAR gamma; PTEN Phosphohydrolase; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Burden | 2010 |
A toxicology study to evaluate the embryotoxicity of metformin compared with the hypoglycemic drugs, the anticancer drug, the anti-epileptic drug, the antibiotic, and the cyclo-oxygenase (COX)-2 inhibitor.
Topics: 3T3 Cells; Animals; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Agents; Cell Differentiation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Embryonic Stem Cells; Fibroblasts; Fluorouracil; Gene Expression Regulation, Developmental; Hypoglycemic Agents; Metformin; Mice; Penicillins; Phenytoin; Risk Assessment; Rosiglitazone; Sulfonamides; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
Topics: Active Transport, Cell Nucleus; Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta Catenin; Cell Line, Tumor; Cell Nucleus; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Frizzled Receptors; Humans; Ovarian Neoplasms; Paclitaxel; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription, Genetic; Wnt Proteins | 2015 |
Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress.
Topics: Adipocytes; Adipogenesis; Animals; Bone Marrow; Cell Line; Female; Fluorouracil; Hematopoiesis; Hematopoietic Stem Cells; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Myelopoiesis; PPAR gamma; Rosiglitazone; Stress, Physiological; Thiazolidinediones | 2016 |
Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice.
Topics: Animals; Blotting, Western; Cytokines; Fluorouracil; Mice; Mice, Inbred C57BL; Mouth Mucosa; PPAR gamma; Real-Time Polymerase Chain Reaction; Rosiglitazone; Stomatitis | 2018 |